



HISTORICAL TIMELINE OF COVID-19 VACCINES/DOSES

April 18, 2024

The following table provides a historical timeline of which vaccine/dose has been available for adults in the U.S. to receive and the timeframe in which that vaccine/dose was available.*

Vaccine Name/Type	Dose(s)	Dates Delivered	Notes
Pfizer-BioNTech			
Pfizer-BioNTech primary series	2	December 14, 2020 thru April 18, 2023	Individuals aged 16 years and older, after 1 st dose, individual received 2 nd dose 3 weeks later
Pfizer-BioNTech (monovalent) booster	1	September 25, 2021 thru September 1, 2022	First administered at least 6 months after primary series to individuals aged 65 and older; 18 through 64 years of age at high risk of severe COVID-19; and 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19. As of November 21, 2021, all individuals 18 years of age and older were eligible to receive a booster at least 6 months after primary series.
Pfizer-BioNTech additional (monovalent) booster dose	1	March 29, 2022 thru September 1, 2022	Certain immunocompromised individuals and individuals over the age of 50 who received an initial booster dose at least 4 months ago are eligible
Pfizer-BioNTech bivalent booster	1	September 2, 2022 thru August 2023	Individuals aged 12 years and older at least 2 months after primary series or prior monovalent booster dose
Pfizer-BioNTech bivalent booster (additional dose)	1	April 18, 2023 thru August 2023	Individuals aged 65 and older or who are immunocompromised are eligible at least 4 months after their initial bivalent booster
Pfizer-BioNTech 2023-2024 vaccine	1	September 12, 2023 thru TBD	At least 8 weeks after any previous dose
Pfizer-BioNTech 2023 – 2024 vaccine	1	February 28, 2024	Individuals aged 65 and older at least 4 months after their last dose of 2023-2024 monovalent vaccine

Moderna			
Moderna primary series	2	December 18, 2020 thru April 18, 2023	Adults aged 18 years and older, after 1 st dose, individual received 2 nd dose 1 month later
Moderna (monovalent) booster	1	October 20, 2021 thru September 1, 2022	First administered 6 months after primary series to individuals aged 65 and older; 18 through 64 years of age at high risk of severe COVID-19; and 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19. As of November 21, 2021, all individuals 18 years of age and older were eligible to receive a booster at least 6 months after primary series.
Moderna additional (monovalent) booster dose	1	March 29, 2022 thru September 1, 2022	Certain immunocompromised individuals and individuals over the age of 50 who received an initial booster dose at least 4 months ago are eligible
Moderna bivalent booster	1	September 2, 2022 thru August 2023	Individuals ages 18 years and older at least 2 months after primary series or prior monovalent booster dose
Moderna bivalent booster (additional dose)	1	April 18, 2023 thru August 2023	Individuals aged 65 and older or who are immunocompromised are eligible at least 4 months after their initial bivalent booster
Moderna 2023-2024 vaccine	1	September 12, 2023 thru TBD	At least 8 weeks after any previous dose.
Johnson & Johnson/Janssen			
Johnson & Johnson/Janssen	1	February 27, 2021 thru May 6, 2023	Individuals ages 18 years and older
Johnson & Johnson/Janssen booster	1	October 20, 2021 thru May 6, 2023	Administered at least 2 months after primary dose
			On December 16, 2021, CDC and ACIP preferentially recommended the use of mRNA vaccines over the Johnson & Johnson/Janssen vaccine. On May 5, 2022, the FDA strictly limited the use of the Johnson & Johnson/Janssen COVID-19 vaccine because of the rare but serious risk of blood clots.

Novavax			
Novavax primary series	2	July 13, 2022 thru September 2023	In adults aged 18 years and older, after 1 st dose, individual received 2 nd dose 3 weeks later
Novavax (monovalent) booster	1	October 19, 2022 thru September 2023	Individuals aged 18 years and older at least 6 months after primary series
Novavax 2023-2024 vaccine	1	October 4, 2023 thru TBD	Individuals 12 years and older <ul style="list-style-type: none"> • Initial vaccination: 2 doses of updated (2023–2024) Novavax vaccine • Previously vaccinated with any original monovalent or bivalent COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech, Janssen): 1 dose of updated (2023–2024) Novavax vaccine

*Table was compiled using the following sources:

- U.S. Department of Health and Human Services. *COVID-19 Vaccines*. September 13, 2023. Available at: <https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html>.
- Centers for Disease Control and Prevention. *Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States*. October 6, 2023. Available at: [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#:~:text=Use%20of%20COVID%2D19%20Vaccines%20in%20the%20U.S.,Formula\)%20Novavax%20COVID%2D19%20Vaccine](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#:~:text=Use%20of%20COVID%2D19%20Vaccines%20in%20the%20U.S.,Formula)%20Novavax%20COVID%2D19%20Vaccine).
- Centers for Disease Control and Prevention. *Stay Up to Date with COVID-19 Vaccines*. March 7, 2024. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>.